| Application no. and date | 09795720.3 (espacenet) (Federated) (European Patent Register), 20091218 | | Patent/reg. no. and date | DK/EP 2424513, 20150520 | | Publication date | 20120307 | | Priority no. and date | US 174170 P, 20090430, EP 09006030, 20090430 | | EP pub. no. and date |
EP 2424513 20120307 | | Effective date | | | Applicant/owner | The United States of America as represented by the
Department of Health and Human Services, 200 Independence Avenue, S.W.
Washington, DC 20201, US,
Santhera Pharmaceuticals (Schweiz) AG, Hammerstrasse 49
4410 Liestal, CH | | Applicant ref. no. | 63925 | | Inventor | MEIER, Thomas, Wintergasse 10
CH-4056 Basel, CH,
BIELEKOVA, Bibiana, 4109 Wexford Drive
Kensington
MD 20895, US,
MCFARLAND, Henry, F., 9201 Brink Road
Gaithersburg
MD 20882, US | | Representative | Larsen & Birkeholm A/S Skandinavisk Patentbureau, Banegårdspladsen 1, 1570 København V | | Opponent | | | IPC Class | A61K 31/122 (2006.01) , A61P 25/00 (2006.01) | | Title | Quinonderivat-2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinon til behandling af primær progressiv multipel sklerose | | Int. application no. | EP2009009148 | | Int. publication no. | WO2010124713 | | Related patent (certificate) | | | Status | Bortfaldet | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
